Get the Stockscreener App
245.58
0.45%
-1.10
After Hours:
242.31
-3.27
-1.33%
Beone Medicines Ltd Adr stock is traded at $245.58, with a volume of 406.95K.
It is down -0.45% in the last 24 hours and down -5.48% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
See More
Previous Close:
$246.68
Open:
$248
24h Volume:
406.95K
Relative Volume:
0.85
Market Cap:
$349.54B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-39.36
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
+1.72%
1M Performance:
-5.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$240.21
$248.00
1-Week Range:
$235.35
$248.08
52-Week Range:
$172.67
$287.88
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare ONC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
China approves novel HER2-targeted therapy for BTC - Investing.com Australia
China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com UK
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.
BeiGene completes corporate re-domiciliation to Switzerland - Investing.com
BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com India
Daiwa Raises BEIGENE's TP to HKD180; Brukinsa Sales Growth Outpaces Competitors - AASTOCKS.com
BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India
Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX
BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins patent challenge against Pharmacyclics - Investing.com
BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India
BeiGene wins US patent dispute over cancer drug - Investing.com
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beone Medicines Ltd Adr Stock (ONC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong | Chair, Scientific Advisory Brd |
May 13 '25 |
Sale |
223.50 |
41,760 |
9,333,272 |
0 |
| OYLER JOHN | Chief Executive Officer |
May 09 '25 |
Option Exercise |
0.50 |
4,055,415 |
2,027,708 |
10,154,040 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Option Exercise |
6.50 |
41,760 |
271,440 |
41,760 |
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Sale |
242.66 |
41,760 |
10,133,595 |
0 |
1.13%
3.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):